What are the current clinical guidelines for diagnosing and treating the different types of anemia, including iron deficiency, vitamin B12 deficiency, folate deficiency, anemia of chronic disease, and renal anemia?

Clinical Guidelines for Diagnosis and Treatment of Anemia

Diagnostic Approach

Begin by measuring hemoglobin to define anemia using WHO criteria: <130 g/L in men over 15 years, <120 g/L in non-pregnant women over 15 years, and <110 g/L in pregnant women 1. However, use your local laboratory's lower limit of normal if it aligns with these WHO thresholds 1.

Initial Laboratory Evaluation

When anemia is confirmed, obtain a complete blood count with red cell indices (MCV, MCH), reticulocyte count, and serum ferritin 2, 1. The mean cell hemoglobin (MCH) is more reliable than MCV as it's less affected by storage conditions and counting machines 1.

For iron status assessment:

• Serum ferritin <15 μg/L is highly specific (99%) for iron deficiency 1
• Ferritin <30 μg/L generally indicates low iron stores 1
• In inflammatory conditions, use ferritin <45 μg/L as the threshold (specificity 92%) 1
• Ferritin >150 μg/L excludes absolute iron deficiency even with inflammation 1
• Add transferrin saturation (TSAT) for functional iron deficiency assessment 2, 3

Critical pitfall: Ferritin is an acute phase reactant and can be falsely normal in inflammatory states despite true iron deficiency 1.

Pattern Recognition by Cell Size

Microcytic/Hypochromic (Low MCV/MCH):

• Most commonly iron deficiency
• Consider Hb electrophoresis if microcytosis with normal iron studies, especially in appropriate ethnic backgrounds, to exclude thalassemia 1
• MCV typically reduced out of proportion to anemia in thalassemia 1

Macrocytic (High MCV):

• Look for macro-ovalocytes and hypersegmented neutrophils on blood film 4
• Measure serum vitamin B12 and folate levels 4
• If unavailable, treat empirically with both, starting vitamin B12 10-14 days before folate to prevent precipitating neurological symptoms 4

Normocytic/Normochromic:

• Most common in CKD-related anemia 2
• Consider anemia of chronic disease
• Evaluate reticulocyte count to assess bone marrow response 2

Special Populations Requiring Modified Thresholds

Standard hemoglobin definitions may not apply in: pregnancy, menstruating women, high altitude residents, smokers, men ≥70 years, non-Caucasian races, chronic lung disease, and hemoglobinopathies 2.

---

Treatment by Anemia Type

Iron Deficiency Anemia

Oral iron is first-line therapy at 2-3 mg/kg elemental iron daily in children 4 and standard adult dosing in non-CKD populations 1, 3.

Switch to intravenous iron when:

• Chronic kidney disease patients, particularly on hemodialysis 3, 5
• Chemotherapy-induced anemia 3
• Intolerance or failure of oral iron 1
• Need for rapid correction 3

For CKD patients specifically:

• The 2026 KDIGO guidelines introduce more proactive thresholds for IV iron, especially in hemodialysis 6, 5
• Target ferritin 200-500 μg/L (not exceeding 500-800 μg/L) 3
• Target TSAT 20-50% depending on specific situation 3

Treatment targets:

• Hemoglobin 10-12 g/dL or normalization 3
• Serum ferritin >100-200 μg/L 3

Vitamin B12 Deficiency

Use parenteral vitamin B12 for:

• Pancytopenia
• Severe anemia
• Developmental delay
• Infantile tremor syndrome
• Any situation requiring rapid response 4

Oral vitamin B12 is acceptable for mild-to-moderate anemia without neurological symptoms 4.

Critical timing: Start vitamin B12 10-14 days before folic acid to prevent neurological deterioration 4.

Folate Deficiency

Treat with oral folic acid supplementation, but never before ruling out or treating vitamin B12 deficiency 4.

Anemia of Chronic Disease

Best treatment is addressing the underlying chronic disorder 7. This represents functional iron deficiency where iron absorption and release are blocked as a defense mechanism 7.

Differentiation from iron deficiency is crucial:

• ACD: Normal or elevated ferritin with low TSAT
• Iron deficiency: Low ferritin
• Combined: Ferritin <100 μg/L with inflammatory markers elevated 7

Renal Anemia (CKD)

Screen CKD patients at minimum yearly for anemia 2. More frequent monitoring needed in diabetics who develop anemia earlier and at higher rates 2.

Treatment hierarchy per 2026 KDIGO:

• Erythropoiesis-stimulating agents (ESAs) remain preferred first-line therapy due to cardiovascular safety concerns with HIF-prolyl hydroxylase inhibitors (HIF-PHIs) 5
• IV iron per proactive thresholds 6, 5
• HIF-PHIs are available but have methodological limitations in trials and cardiovascular safety concerns 5

Important consideration: Abnormalities in two or more cell lines (WBC, hemoglobin, platelets) warrant hematology consultation 2.

---

Post-Treatment Prophylaxis

After completing treatment for nutritional anemia, continue prophylactic iron-folic acid supplementation as prescribed under public health guidelines 4. Screen infants for anemia at 9 months during immunization visits 4.

---

Investigation Thresholds

Investigate for underlying pathology (especially GI bleeding) when:

• Hemoglobin <110 g/L in men or <100 g/L in non-menstruating women 1
• However, consider investigation at any level of anemia with confirmed iron deficiency, as these cut-offs miss some colorectal cancers, especially in men 1
• Iron deficiency in non-menstruating CKD patients not on ESAs without known blood loss 2

---

Common Pitfalls to Avoid

1. Transfusion overuse: 36.6% of transfusions in one study had no guideline-directed indication 8
2. Inadequate iron assessment: Only 19% had transferrin saturation measured in one CKD cohort 2
3. Starting folate before B12: Can precipitate neurological symptoms 4
4. Missing inflammation: Ferritin appears normal despite true iron deficiency 1
5. Undertreating with iron/ESA: Iron and ESA therapy rates are too low in practice 8

Higher adherence to diagnostic guidelines correlates with better therapeutic adherence and greater hemoglobin increases 8.